Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, a fully human IgG1 monoclonal antibody directed against IGF-1R, was expected...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Naing, Aung, Kurzrock, Razelle, Burger, Angelika, Gupta, Sachin, Lei, Xiudong, Busaidy, Naifa, Hong, David, Chen, Helen X., Doyle, Lawrence A., Heilbrun, Lance K., Rohren, Eric, Ng, Chaan, Chandhasin, Chandtip, LoRusso, Patricia
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176947/
https://ncbi.nlm.nih.gov/pubmed/21750201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2979
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares